Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Waiver under 18 U.S.C. § 208(b)(3)

Nelson Watts, M.D.

Committees: Joint Nonprescription Drugs Advisory Committee and Endocrinologic

and Metabolic Drugs Advisory Committee Meeting

Meeting Date: January 23, 2006

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to agenda item new drug application (NDA) 21-887, proposing over-the-counter (OTC) use of Orlistat (tetrahydrolipstatin) 60 milligram (mg) capsules, sponsored by GlaxoSmithKline Consumer Healthcare, L.P., an associate of GlaxoSmithKline PLC, to promote weight loss in overweight adults when used along with a reduced calorie and low fat diet, I am eligible to receive a waiver under 18 U.S.C. § 208(b)(3).

Type of Interest	Nature	Magnitude
Consulting (Advisory Board) on unrelated matter	Sponsor	Less than \$10,001 per year
Consulting (Advisory Board) on unrelated matter	Competitor	Less than \$10,001 per year
Consulting (Advisory Board) on unrelated matter	Competitor	Less than \$10,001 per year
Consultant on unrelated matter	Competitor	Less than \$10,001 per year
Speaking	Competitor	From \$5,001 to \$10,000 per year
I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waiver is not valid.		
/s/	$-\frac{12/22}{2}$	(05
Signature of SGE	Date	